HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recalls: FDA Reports Salmonella Contamination In More Kratom Supplements

This article was originally published in The Rose Sheet

Executive Summary

FDA's list of recalls of health, beauty and wellness products that have been categories from April 25 through June 20 include products from nine other kratom supplement marketers. Drug-spiked products marketed as supplements also are included in FDA's list for the period.

You may also be interested in...



Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA

American Kratom Association accuses FDA of using “inaccurate, extrapolated and distorted” information on adverse events and deaths allegedly associated with the use of kratom to justify scheduling it as a controlled substance. After FDA Commissioner Gottlieb says the criticism is unfounded and kratom has no future as a dietary ingredient in the US, the group asks for joint meeting with NIDA to discuss "public health policy that allows for consumers to safely use natural kratom."

Las Vegas Kratom Marketer Rolls Dice On FDA's Mandatory Recall Authority

FDA for the first time exercises its mandatory recall authority over food and supplement products to order Triangle Pharmanaturals, which opened for business in Las Vegas in April 2017, to recall all of the kratom-containing products it has distributed and to cease distributing additional products.The agency also notes in the announcement that it continues to scrutinize kratom's safety unrelated to contamination.

Verrica’s Molluscum Product Set Back By FDA Usage Questions

Verrica got a complete response rather than approval for its drug/device combo for molluscum, but says the FDA only needs additional information on product changes for safe usage by clinicians.

Topics

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel